|
A multicenter analysis of melanoma recurrence following adjuvant anti-PD1 therapy. |
|
|
Travel, Accommodations, Expenses - Merck Sharp & Dome |
|
|
Honoraria - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kyocera; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra; Vitaccess |
Consulting or Advisory Role - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kyocera; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra; Vitaccess |
Research Funding - Achilles Therapeutics (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Immunocore (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer; Roche/Genentech |
|
Alexander Noor Shoushtari |
Consulting or Advisory Role - Bristol-Myers Squibb; Castle Biosciences; Immunocore |
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb; Immunocore; Xcovery |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
Honoraria - Bristol-Myers Squibb; MSD; Novartis |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre |
|
|
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst) |
Research Funding - Bristol-Myers Squibb (Inst); NanoString Technologies (Inst); Novartis (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
|
Travel, Accommodations, Expenses - Roche |
|
|
Consulting or Advisory Role - Merck; Pfizer; Pierre Fabre |
Travel, Accommodations, Expenses - MSD; Pierre Fabre |
|
|
Honoraria - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech |
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche |
Speakers' Bureau - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Roche/Genentech |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme; OncoSec |
|
|
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pfizer/EMD Serono; Roche |
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Cardinal Health; Castle Biosciences; Incyte |
|
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Deciphera (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Provectus (Inst); Reata Pharmaceuticals (Inst) |
Travel, Accommodations, Expenses - Cardinal Health; Castle Biosciences; Incyte; Massachusetts General Hospital; PCME, Rockpointe; Socrates Analytics |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Incyte; Merck Sharp & Dome; Novartis; Pierre Fabre; Roche |
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Merck Sharp & Dome; Novartis; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; Roche |
|
|
Honoraria - Bristol-Myers Squibb; Merck; Pierre Fabre |
Consulting or Advisory Role - Aduro Biotech; Array BioPharma; Bristol-Myers Squibb; Incyte; MERCK; Novartis; OncoSec; Pierre Fabre |
Research Funding - BMS Brazil (Inst); Merck (Inst) |